

Remarks

Currently Claims 1-9, 13 and 15-20 are pending. Claims 10-12 and 14 are canceled.

Claims 1-9, and 13 are amended herein. Claim 1 is amended to change "represents" to "is" or "are." Claims 1 and 9 are amended to add subscripts in the formulas. Claims 3-8 and 13 are amended to remove multiple dependencies for the purpose of reducing claim fees. Claims 2, 5 and 7-8 are amended to remove parenthetical clauses. Claim 9 is amended to remove the second recited process. The amendments do not narrow the scope of the claims and are not being made for reasons of patentability. No new matter is added.

New claims 15-20 are added. New claims 15-17 recite embodiments previously encompassed by claims 2, 5 and 9, respectively. Original claim 14 is rewritten as new claims 18-20. No new matter is added.

The title has been amended to correct a clerical error. The specification has been amended to recite related applications and to provide an abstract on a separate page. No new matter is added.

Entry of the foregoing amendments is respectfully requested.

Applicants respectfully submit that the instant application is in condition for substantive examination, which action is respectfully requested. The Examiner is invited to contact the undersigned at (919) 483-8222, to discuss this case, if desired.

PI4861USw

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'L. Morgan', with a long horizontal flourish extending to the right.

Lorie Ann Morgan
Attorney for Applicants
Registration No. 38,181

Date: 3 January, 2005
GlaxoSmithKline Inc.
Five Moore Drive, PO Box 13398
Research Triangle Park
North Carolina 27709
(919) 483-8222
fax: (919) 483-7988
Lorie.A.Morgan@gsk.com